CPIX - Cumberland Pharmaceuticals Inc. Stock Analysis

Stock Taper

OPPORTUNITY RADAR SCREENER COMPARE ANY 2 STOCKS

CPIX

CUMBERLAND PHARMACEUTICALS INC.

NASDAQ

$6.98

▲ UP 1.31% (0.09)

KEY STATISTICS

Market Cap$103.98 M

52w High$9.28

52w Low$1.85

Dividend Yield19.31%

FrequencyIrregular

P/E-17.45

Volume50.28K

Shares Out.14.98M

COMPANY

LEADERSHIP

CHIEF EXECUTIVE

A. J. Kazimi

COMPENSATION 2026

Salary$702,000

Stock Awards$0

Incentive Plan Pay$0

All Other Comp.$2,269

Total$1,167,269

ABOUT

SECTOR

Healthcare

WENT PUBLIC

August 11, 2009

METHOD OF GOING PUBLIC

IPO

FULL TIME EMPLOYEES

UPCOMING EARNINGS

DateNov 3, 2026

DayTuesday

Rev. Est.$8.50M

NOV

TUE

ETFS HOLDING THIS STOCK

ETFS HOLDING

LISTED HERE

RANKED BY POSITION SIZE

INSTITUTIONAL OWNERSHIP

SHARES OWNED

21.98%

HOLDERS

TOP 8 OF 52 · RANKED BY POSITION SIZE

Millennium Management LLC

Renaissance Technologies LLC

Blackrock Institutional Trust Company, N.A.

381.7K sh

$2.1M

Perceptive Advisors LLC

341.1K sh

$1.36M

Dimensional Fund Advisors LP

PRICE

$6.98 ▲ UP 1.31% (+$0.09)

About Cumberland Pharmaceuticals Inc.

https://www.cumberlandpharma.com ↗

Cumberland Pharmaceuticals Inc. develops and commercializes prescription products for hospital acute care, gastroenterology, rheumatology, and oncology, including treatments for poisoning, pain, infections, constipation, and inflammatory diseases.

INDUSTRY

Drug Manufacturers - Specialty & Generic

A PRODUCT CUMBERLAND PHARMACEUTICALS INC. IS KNOWN FOR

Talicia®

Talicia® is an FDA-approved oral capsule combining antibiotics and a proton pump inhibitor for H. pylori treatment, representing a key growth opportunity for Cumberland through its partnership with RedHill Biopharma.

COMPETITORS

COMPETITOR

Cumberland Pharmaceuticals in 2025

SENTIMENT: + POSITIVE

REGULATORY · DECEMBER 2025

Cumberland Pharmaceuticals Stock Surges 76% After Favorable CMS Reimbursement Update for Caldolor®

In December 2025, Cumberland Pharmaceuticals experienced a significant, multi-day stock rally after announcing a key reimbursement update from the Centers for Medicare & Medicaid Services (CMS) for its non-opioid pain management drug, Caldolor. This event was the primary catalyst for a dramatic increase in the company's market capitalization, signaling strong investor optimism about the drug's commercial momentum.

PARTNERSHIP · Q3 2025 · IN PROGRESS

Cumberland Pharmaceuticals Forms Joint Venture with RedHill Biopharma to Co-Commercialize Talicia®, Expanding its Gastroenterology Portfolio

In a significant strategic move to bolster its product pipeline, Cumberland Pharmaceuticals entered into a joint commercialization venture with RedHill Biopharma for Talicia®, an FDA-approved treatment for Helicobacter pylori infection. This partnership establishes a new jointly owned company, Talicia Holdings, Inc., where Cumberland will lead the U.S. sales and distribution, and both companies will equally share the net revenues.